CompletedPhase 3

Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)

62 participantsStarted 2004-05

Plain-language summary

The purpose of this study is to determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in patients who have a history of worsening asthma after exercise.

Who can participate

Age range15 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with mild-to-moderate asthma Exclusion Criteria: * Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection * Patient is, other than asthma, not in good, stable health * The Primary Investigator will evaluate whether there are other reasons why the patient may not participate

What they're measuring

Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)

Timeframe: Pre-exercise baseline measurement and 0-60 minutes after the exercise challenge performed 2 hours after a single oral dose

Trial details

NCT IDNCT00090142

SponsorOrganon and Co

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2004-10

Results submitted2009-09-22

View on ClinicalTrials.gov More Asthma, Exercise-Induced trials